Tags

Type your tag names separated by a space and hit enter

Tardive dyskinesia and other movement disorders secondary to aripiprazole.
Mov Disord. 2011 Jan; 26(1):147-52.MD

Abstract

The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical (first-generation) antipsychotics, but other dopamine receptor blocking drugs and atypical (second- and third-generation) neuroleptics are emerging as an important cause of TD. We reviewed the medical records of patients with TD seen at the Baylor College of Medicine Movement Disorders Clinic between 2002 and 2010 to identify patients with TD associated with aripiprazole. Among 236 patients with TD seen over the specified period, 8 (3.4%) were found to have aripiprazole-associated TD. In 5 patients, TD occurred after exclusive exposure to aripiprazole. The mean age at onset was 55.8 ± 14.8 years with a female predominance. The average duration of treatment with aripiprazole was 18.4 ± 26.4 months. Oro-bucco-lingual stereotypy was seen in all patients. In most patients, TD did not spontaneously improve after stopping aripiprazole. Of the 5 patients treated with tetrabenazine, 4 improved during follow-up. Although aripiprazole, a third generation antipsychotic, has been promoted to have a low risk of TD, the drug accounts for about 3.5% of patients with TD evaluated in a movement disorders clinic. This largest reported series draws attention to the growing incidence of TD and other drug-induced movement disorders associated with "atypical antipsychotics."

Authors+Show Affiliations

Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20818603

Citation

Peña, Maria Sierra, et al. "Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 26, no. 1, 2011, pp. 147-52.
Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26(1):147-52.
Peña, M. S., Yaltho, T. C., & Jankovic, J. (2011). Tardive dyskinesia and other movement disorders secondary to aripiprazole. Movement Disorders : Official Journal of the Movement Disorder Society, 26(1), 147-52. https://doi.org/10.1002/mds.23402
Peña MS, Yaltho TC, Jankovic J. Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole. Mov Disord. 2011;26(1):147-52. PubMed PMID: 20818603.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tardive dyskinesia and other movement disorders secondary to aripiprazole. AU - Peña,Maria Sierra, AU - Yaltho,Toby C, AU - Jankovic,Joseph, Y1 - 2010/09/03/ PY - 2010/03/24/received PY - 2010/05/17/revised PY - 2010/07/13/accepted PY - 2010/9/7/entrez PY - 2010/9/8/pubmed PY - 2011/6/7/medline SP - 147 EP - 52 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 26 IS - 1 N2 - The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical (first-generation) antipsychotics, but other dopamine receptor blocking drugs and atypical (second- and third-generation) neuroleptics are emerging as an important cause of TD. We reviewed the medical records of patients with TD seen at the Baylor College of Medicine Movement Disorders Clinic between 2002 and 2010 to identify patients with TD associated with aripiprazole. Among 236 patients with TD seen over the specified period, 8 (3.4%) were found to have aripiprazole-associated TD. In 5 patients, TD occurred after exclusive exposure to aripiprazole. The mean age at onset was 55.8 ± 14.8 years with a female predominance. The average duration of treatment with aripiprazole was 18.4 ± 26.4 months. Oro-bucco-lingual stereotypy was seen in all patients. In most patients, TD did not spontaneously improve after stopping aripiprazole. Of the 5 patients treated with tetrabenazine, 4 improved during follow-up. Although aripiprazole, a third generation antipsychotic, has been promoted to have a low risk of TD, the drug accounts for about 3.5% of patients with TD evaluated in a movement disorders clinic. This largest reported series draws attention to the growing incidence of TD and other drug-induced movement disorders associated with "atypical antipsychotics." SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/20818603/Tardive_dyskinesia_and_other_movement_disorders_secondary_to_aripiprazole_ L2 - https://doi.org/10.1002/mds.23402 DB - PRIME DP - Unbound Medicine ER -